A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis

“…[15][16][17][18][19][20][21][22][23][24] We performed 3 different analyses. The first concerned HIT outcome based on RCTs from category A.…”

Venous Thromboembolism Prophylaxis in the General Surgical Patient

“…Both enoxaparin and dalteparin have been shown to reduce the incidence of DVT in patients undergoing general surgery to rates of approximately 6 to 8%; however, direct comparison studies have not been conducted. 75,78 LMWHs appear to be effective in VTE prophylaxis, even in patients with cancer. 76,77,79,80 The incidence of VTE in patients with cancer who were given enoxaparin was slightly lower than that observed in patients given UFH (14.7% vs 18.2%) in a study of patients undergoing abdominal surgery for malignant disease (N = 1115).…”

“…[73][74][75][76][85][86][87] Advantages of LMWHs over UFH include a higher anti-Xa activity compared with antithrombin activity, better bioavailability at low doses, no monitoring required, and a longer half-life (4 hours vs 0.5 to 2 hours), allowing for once-daily dosing in some patients. However, a long half-life can sometimes be a disadvantage in the case of bleeding complications.…”

The long path to NOAC

“…Our research group was involved in many detailed investigations concerning the preclinical research and development of several LMWH preparations for the prophylaxis of venous thromboembolism (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). For example, in the first thrombosis treatment study with the LMWH certoparin, we investigated whether it should be administered subcutaneously or intravenously.…”